Uncategorized Archives - Page 1009 of 1028

FridaySep 23, 2016 2:42 pm

ICF (ICFI) Unveils New Brand to the Marketplace

On September 20, 2016, ICF (NASDAQ: ICFI) launched its new brand to the marketplace. The consulting and technology services provider’s new branding includes a new logo, website, and corporate positioning. ICF celebrated its 10th anniversary as a publicly-traded company this year and coordinated the unveiling of the new brand alongside it. In a news release, Sudhakar Kesavan, ICF’s CEO and chairman, stated, “This is the ideal time for ICF to reinforce our brand in a more cohesive and meaningful way. Our new positioning and visual identity better represent ICF’s capabilities as one of the only fully integrated consulting and technology…

FridaySep 23, 2016 10:57 am

Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (LB6A.F) Included in the Canadian Securities Exchange Composite Index

Before the opening bell, Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) announced its inclusion on the Canadian Securities Exchange (CSE) Composite index. Criteria for inclusion on the CSE Composite index include active listing on the CSE, a market capitalization of at least $5 million and a seasoning requirement. At each quarterly rebalance, companies included in the index are assessed to ensure a minimum market capitalization of at least $4 million, with companies that fail to meet this criteria being subject to index deletion. The market cap of Laguna Blends was listed at $6.34 million as of September 19,…

FridaySep 23, 2016 9:16 am

EnteroMedics, Inc. (ETRM) is Pulling its Weight in the Fight Against Obesity

EnteroMedics, Inc. (NASDAQ: ETRM) aims to make America leaner and fitter. The company, based in St. Paul, Minnesota, provides safe, reliable and effective products and therapies to treat obesity and metabolic disorders. Its signature technology, the vBloc® vagal blocking therapy delivered via the Maestro® Rechargeable System, is gaining increasing acceptance both domestically and abroad. vBloc® offers the overweight and the obese relief from those extra pounds that, all too often, trigger a variety of problematic medical conditions. Overweight and obesity are global problems, but America appears to have taken the cake. The National Institute of Diabetes and Digestive and Kidney…

ThursdaySep 22, 2016 3:21 pm

GSK (GSK) Shingles Vaccine Phase III Study Shows High Efficacy in Adults Aged 70 and Over

An investigational shingles vaccine developed by global pharmaceutical and healthcare company GlaxoSmithKline (NYSE: GSK) is showing high efficacy against the ailment and various complications in adults over 70, according to a press release issued by the company on Wednesday, September 14. The findings are included in the results of a randomized phase III study (ZOE-70) of the Shingrix™ vaccine, published in the New England Journal of Medicine. The ZOE-70 study, conducted on more than 14,800 subjects in North America, Latin America, Europe and Asia-Pacific, shows that the candidate shingles vaccine, administered in two doses, has an efficacy rate of 90%…

ThursdaySep 22, 2016 2:44 pm

Function(x) Inc. (FNCX) Begins Trading on Split-Adjusted Basis

Function(x) Inc. (NASDAQ: FNCX) recently announced that it has started trading on a reverse split-adjusted basis as of the opening of the market on Friday, September 16, 2016. The company’s common stock shares will be traded at a ratio of 1-for-20 shares. The reverse stock split was approved by Function(x)’s board of directors the previous week in order for the company to recover and stay within the lowest closing bid price of $1.00 per share to maintain its NASDAQ status. Function(x) will continue to trade under the same ticker symbol of FNCX. As a result, every 20 pre-split outstanding shares…

ThursdaySep 22, 2016 11:29 am

Horizon Pharma plc (HZNP) is “One to Watch”

Headquartered in Dublin, Ireland, Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company whose aim is to improve lives with the recognition, development, acquisition, and commercialization of accessible medicines to meet a variety of patient medical needs. Horizon Pharma now markets nine key products through its orphan, rheumatology, and primary care business units. Products include ACTIMMUNE®, Buphenyl®, Duexis®, KRYSTEXXA®, Migergot®, PENNSAID® 2%, Ravicti®, Rayos®, and Vimovo®. These products are used to reduce the frequency and severity of serious infections, treat patients with urea cycle disorders, relieve signs and symptoms of rheumatoid arthritis and osteoarthritis, decrease the risk of developing upper gastrointestinal…

ThursdaySep 22, 2016 9:09 am

iGambit, Inc. (IGMB) Leaning on Seasoned Leadership Team to Guide Acquisition-Based Growth Model

iGambit, Inc. (OTCQB: IGMB) is a diversified holding company focused primarily on the acquisition of early-stage technology firms with strong growth potential that’s easily recognized in the public arena. Leveraging the considerable industry experience of its board of directors and management team, iGambit offers talented entrepreneurs an opportunity to focus their time and energy on building a business instead of searching out investors or raising capital. Following acquisition, iGambit provides the capital and management expertise required to help its partner firms flourish with the intention of ‘spinning off’ the acquisition to the benefit of both the newly independent business and…

WednesdaySep 21, 2016 3:50 pm

SITO Mobile (SITO) Announces Pricing of $10 Million Underwritten Public Offering

Leading mobile engagement platform SITO Mobile Ltd. (NASDAQ: SITO) on Friday, September 16, announced a $10 million underwritten public offering. The offering is expected to close on Tuesday, September 21. The underwritten public offering consists of 2,666,667 shares of common stock at an offering price of $3.75 each. SITO Mobile also made available a 30-day option that would allow underwriters to purchase up to 400,000 additional shares at the same price. The decision is designed to cover overallotments that result from the underwritten public offering. The New Jersey company expects gross proceeds of $10 million and approximately $9.3 million after…

WednesdaySep 21, 2016 3:32 pm

MabVax (MBVX) Tackling Cancer with Diagnostics and Therapeutics

Recently, David Hansen, the CEO of MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), spoke to Jane King of Small Cap Nation about current developments at the clinical-stage biotechnology company. They were joined by Jeffrey Kraws, founder and senior analyst at Crystal Research Associates. MabVax is an oncology drug development company with a number of technologies to discover antibodies from patient immune responses against their cancers. The antibodies so derived from humans are then used to develop products for the diagnosis and treatment of metastatic solid tumor cancers. Human-derived antibodies have less chance of being rejected by the body, as CEO David…

WednesdaySep 21, 2016 12:14 pm

Pay-by-Text™ from Singlepoint, Inc. (SING) Makes Mobile Payments as Easy as SMS

A recent feature in Fortune magazine titled ‘How mobile payments will grow in 2016’ (http://nnw.fm/DrEs0) shows the rosy future that lies before Singlepoint, Inc. (OTC: SING). The Fortune piece reports that ‘eMarketer (is) forecasting 210% growth in the total value of mobile payment transactions in 2016—up to $27.05 billion from $8.71 billion’. This is a market that is still in its infancy, and Singlepoint’s Pay-by-Text™ technology is precisely the sort of cutting edge innovation that can establish a niche in it. Despite the promise of easier use and convenience, the Fortune piece reveals that ‘while 52% of North Americans are…